Williams A
Department of Thoracic Medicine, Royal Bournemouth Hospital.
Hosp Med. 1998 Jun;59(6):488-91.
This year will see the launch of the first chlorofluorocarbon (CFC)-free formulation of beclomethasone. Developed by 3M Health Care, its extrafine formulation gives significant benefits resulting from increased lung deposition and improved inhaler technology. Its difference from CFC-propelled inhalers is so marked that it will challenge views about about the risk-benefit profile of beclomethasone.
